0000000000691305

AUTHOR

Erdem Güresir

showing 4 related works from this author

Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 count…

2022

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseBackground: The 2015 Lancet Commission on global surgery identified surgery and anaesthesia as indispensable parts of holistic health-care systems. However, COVID-19 exposed the fragility of planned surgical services around the world, which have also been neglected in pandemic recovery planning. This study aimed to develop and validate a novel index to support local elective surgical system strengthening and address growing backlogs. Methods: First, we performed an international consultation through a four-stage consensus process to develop a multidomain index for hospital-level assess…

MaleHealth system resilience.*COVID-19/epidemiologySocial SciencesSağlık BilimleriGlobal HealthFundamental Medical SciencesClinical Medicine (MED)AnaesthesiasurgeryTIP GENEL & DAHİLİnisu navedene ključne riječiElective backlogMedicine and Health SciencesTOOLKlinik Tıp (MED)610 Medicine & healthMEDICINE GENERAL & INTERNAL11 Medical and Health SciencesKlinik Tıpsurgery; global surgery; health-care systemCovid19NIHR Global Health Unit on Global SurgeryGeneral MedicineHospitalsHospital preparedneTıphealth-care systemElective Surgical ProceduresHEALTH SYSTEMS*PandemicsMedicineFemaleLife Sciences & BiomedicineHumanHälso- och sjukvårdsorganisation hälsopolitik och hälsoekonomiTemel Tıp Bilimleri610 Medicine & healthglobal surgeryGenel TıpCAPACITYCOVIDSurg CollaborativeHospitalMedicine General & InternalGeneral & Internal MedicineHealth SciencesHumansPandemicsScience & TechnologyElective Surgical ProcedurePandemicKirurgiPlanned surgeryCOVID-19Health Care Service and Management Health Policy and Services and Health EconomyCLINICAL MEDICINESettore MED/18Settore MED/18 - Chirurgia Generaleelective surgeryHospital assessmentSystems strengtheningSurgeryHuman medicineMETHODOLOGY[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Erythropoietin neuroprotection is enhanced by direct cortical application following subdural blood evacuation in a rat model of acute subdural hemato…

2013

Recombinant human erythropoietin (EPO) has been successfully tested as neuroprotectant in brain injury models. The first large clinical trial with stroke patients, however, revealed negative results. Reasons are manifold and may include side-effects such as thrombotic complications or interactions with other medication, EPO concentration, penetration of the blood-brain-barrier and/or route of application. The latter is restricted to systemic application. Here we hypothesize that EPO is neuroprotective in a rat model of acute subdural hemorrhage (ASDH) and that direct cortical application is a feasible route of application in this injury type. The subdural hematoma was surgically evacuated a…

MaleIntracranial PressureLesionRats Sprague-DawleyHematomamedicineAnimalsHematoma Subdural AcuteErythropoietinIntracranial pressureCerebral Cortexbusiness.industryGeneral NeuroscienceSubdural hemorrhageVenous bloodmedicine.diseaseCombined Modality TherapyRatsDisease Models AnimalNeuroprotective AgentsCerebral blood flowBlood chemistryErythropoietinAnesthesiamedicine.symptombusinessmedicine.drugNeuroscience
researchProduct

SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study

2021

SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients undergoing surgery during October 2020. Patients from all surgical specialties were included. The primary outcome measure was venous thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 da…

Malepulmonary embolismInternationalitySettore MED/18 - CHIRURGIA GENERALEDeep veinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]infectious diseasesCardiovascularSARS‐CoV‐2surgeryCOVID-19 ; SARS-CoV-2 ; deep vein thrombosis ; pulmonary embolism ; venous thromboembolismCohort StudiesPostoperative ComplicationsAnesthesiologyMedicine and Health SciencesProspective Studies610 Medicine & healthProspective cohort studyLung11 Medical and Health SciencesConfoundingHematologyMiddle AgedThrombosis17 Psychology and Cognitive SciencesCOVID-19; deep vein thrombosis; pulmonary embolism; SARS-CoV-2; venous thromboembolismPulmonary embolismCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolism.medicine.anatomical_structureCohortCOVID-19/complicationsPostoperative Complications/etiologyOriginal ArticleFemalePatient SafetyLife Sciences & BiomedicineCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolismHumanAdultmedicine.medical_specialtyAdolescentClinical Sciencesvenous thromboembolism610 Medicine & healthGlobalSurg CollaborativeVenous Thromboembolism/etiologydeep vein thrombosisNOCOVIDSurg CollaborativeYoung AdultMedicine General & InternalAge DistributionClinical ResearchCOVID‐19General & Internal MedicinemedicineHumansSex DistributionAgedScience & Technologybusiness.industrySARS-CoV-2PreventionNeurosciencesdeep vein thrombosiCOVID-19PneumoniaOdds ratioOriginal Articlesmedicine.diseaseSurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Prospective StudieGood Health and Well BeingAnesthesiology and Pain MedicineHuman medicinePostoperative ComplicationCohort StudiebusinessVenous thromboembolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOB…

2021

Abstract BACKGROUND The CeTeG/NOA-09 trial showed that lomustine/temozolomide chemotherapy prolongs survival for newly diagnosed MGMT-methylated glioblastoma patients. Previous reports on temozolomide monotherapy suggested, that the survival benefit of temozolomide in MGMT-methylated tumors may be restricted to the RTK II methylation subgroup and absent in RTK I and MES subgroups. To identify patients with a particularly strong benefit from CCNU/TMZ, we explored the association of methylation subgroups with outcome after lomustine/temozolomide therapy. METHODS All patients from the CeTeG/NOA-09 trial with sufficiently available tumor tissue (n = 98) underwent 850K methylation array analysis…

Cancer ResearchCombination therapybusiness.industryMedizinPromoterLomustine26th Annual Meeting & Education Day of the Society for Neuro-Oncologymedicine.diseaseSurvival benefitOncologyDNA methylationmedicineCancer researchNeurology (clinical)Temozolomidbusinessmedicine.drugGlioblastomaNeuro-Oncology
researchProduct